# A Study to Evaluate the Pharmacokinetic Interaction and the Safety of AD-236A and AD-236B

> **NCT07730567** · PHASE1 · NOT_YET_RECRUITING · sponsor: **Addpharma Inc.** · enrollment: 44 (estimated)

## Conditions studied

- Hyperlipidemia
- Diabete Type 2

## Interventions

- **DRUG:** Treatment A(AD-236A)
- **DRUG:** Treatment B(AD-236B)
- **DRUG:** Treatment C(AD-236A+AD-236B)

## Key facts

- **NCT ID:** NCT07730567
- **Lead sponsor:** Addpharma Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-07-29
- **Primary completion:** 2026-09-13
- **Final completion:** 2026-09-26
- **Target enrollment:** 44 (ESTIMATED)
- **Last updated:** 2026-07-28


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07730567

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07730567, "A Study to Evaluate the Pharmacokinetic Interaction and the Safety of AD-236A and AD-236B". Retrieved via MORVS 2026-10-20 from https://api.morvs.ai/clinical/NCT07730567. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*